Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ... New England Journal of Medicine 378 (8), 731-739, 2018 | 2503 | 2018 |
Targeting CD38 with daratumumab monotherapy in multiple myeloma HM Lokhorst, T Plesner, JP Laubach, H Nahi, P Gimsing, M Hansson, ... New England Journal of Medicine 373 (13), 1207-1219, 2015 | 1293 | 2015 |
Actively personalized vaccination trial for newly diagnosed glioblastoma N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, ... Nature 565 (7738), 240-245, 2019 | 754 | 2019 |
Preoperative staging of lung cancer with combined PET–CT B Fischer, U Lassen, J Mortensen, S Larsen, A Loft, A Bertelsen, J Ravn, ... New England Journal of Medicine 361 (1), 32-39, 2009 | 694 | 2009 |
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial V Subbiah, U Lassen, E Élez, A Italiano, G Curigliano, M Javle, ... The Lancet Oncology 21 (9), 1234-1243, 2020 | 384 | 2020 |
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients. U Lassen, K Osterlind, M Hansen, P Dombernowsky, B Bergman, ... Journal of clinical oncology 13 (5), 1215-1220, 1995 | 348 | 1995 |
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial B Hasselbalch, U Lassen, S Hansen, M Holmberg, M Sørensen, ... Neuro-oncology 12 (5), 508-516, 2010 | 270 | 2010 |
First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors AR Abdul Razak, M Mau-Soerensen, NY Gabrail, JF Gerecitano, ... Journal of Clinical Oncology 34 (34), 4142-4150, 2016 | 223 | 2016 |
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized … A Omuro, AA Brandes, AF Carpentier, A Idbaih, DA Reardon, ... Neuro-oncology 25 (1), 123-134, 2023 | 205 | 2023 |
A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis BM Fischer, J Mortensen, SW Langer, A Loft, AK Berthelsen, BL Petersen, ... Annals of Oncology 18 (2), 338-345, 2007 | 203 | 2007 |
18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT) U Lassen, G Daugaard, A Eigtved, K Damgaard, L Friberg European Journal of Cancer 35 (7), 1076-1082, 1999 | 201 | 1999 |
Hallmarks of glioblastoma: a systematic review DS Nørøxe, HS Poulsen, U Lassen ESMO open 1 (6), e000144, 2016 | 199 | 2016 |
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction G Daugaard, U Lassen, P Bie, EB Pedersen, KT Jensen, U Abildgaard, ... European journal of heart failure 7 (1), 87-93, 2005 | 170 | 2005 |
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial JS De Bono, N Concin, DS Hong, FC Thistlethwaite, JP Machiels, ... The lancet oncology 20 (3), 383-393, 2019 | 155 | 2019 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma T Plesner, HT Arkenau, P Gimsing, J Krejcik, C Lemech, MC Minnema, ... Blood, The Journal of the American Society of Hematology 128 (14), 1821-1828, 2016 | 138 | 2016 |
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer K Jacobsen, J Bertran-Alamillo, MA Molina, C Teixidó, N Karachaliou, ... Nature communications 8 (1), 410, 2017 | 137 | 2017 |
Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours U Lassen, G Daugaard, A Eigtved, L Højgaard, K Damgaard, M Rørth European journal of nuclear medicine and molecular imaging 30, 396-402, 2003 | 136 | 2003 |
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours HS Poulsen, K Grunnet, M Sorensen, P Olsen, B Hasselbalch, ... Acta Oncologica 48 (1), 52-58, 2009 | 130 | 2009 |
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer C Massard, A Azaro, JC Soria, U Lassen, C Le Tourneau, D Sarker, ... Annals of Oncology 29 (9), 1911-1917, 2018 | 122 | 2018 |
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced … H Borghaei, K Alpaugh, G Hedlund, G Forsberg, C Langer, A Rogatko, ... Journal of Clinical Oncology 27 (25), 4116, 2009 | 113 | 2009 |